Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (108306)	7/9/2007 8:04:29 PM
From: Pogeu Mahone	Respond to of 132070

Northwest Biotherapeutics (NWBT) is a biotechnology company focused on the clinical development of autologous immunotherapy products for cancer. Our technology platform, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system, which are loaded with tumor proteins or antigens. Data from our clinical trials suggest that injection of these cells back into the patient may initiate a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. Our two lead product candidates, DCVax®-Prostate and DCVax®-Brain are entering FDA-allowed late stage clinical trials from which licensure may be possible. Other, related products in our pipeline are ready to enter Phase I clinical trials. Our belief in the advantage of our DCVax® platform is derived from: a focus on ensuringthe high quality and purity of our DCVax® product candidates; our unique therapeutic approach in which immunotherapy is positioned as an adjuvant treatment in patients with low tumor burden; our proprietary, efficient, and low cost method of product manufacturing. Business Strategy NWBT’s mission is to become a leading developer and supplier of cost-effective, non-toxic immunotherapies for primary or adjuvant treatment of cancers. We will focus on those product candidates that allow rapid commercialization to generate return for our shareholders, and that provide the resources required for continued development of potential additional products with longer lead times. We will continue to develop partnerships for commercialization, and marketing of our products with the goal of rapid market penetration without diluting our focus on clinical product development. Initial Product Candidates Our lead product candidates are immunotherapy treatments that are designed to generate and enhance immune system responses to effectively treat multiple types of cancer without toxicity. Northwest Biotherapeutics has recently begun patient accrual in a significant clinical trial, and plans to begin accrual in another clinical trial upon completion of financing: (EDIT: i believe they did financing in june) DCVax®-Brain: We are currently enrolling patients with newly diagnosed Glioblastoma multiforme in a 141-patient, FDA-cleared Phase II clinical trial, which will be conducted at 12-15 clinical centers in the United States. DCVax®-Prostate: We anticipate enrolling patients with non-metastatic, hormone independent prostate cancer in a 612-patient, FDA cleared Phase III clinical trial in 40 to 50 clinical centers in the United